Araki et al reported that urinary L-FABP of more than 5 μg/g Cr may be a predictive marker for renal and cardiovascular prognosis in patients with type 2 diabetes without advanced nephropathy.7 8 Therefore, we evaluated the effect of anagliptin on urinary excretion in patients who had a urinary L-FABP level of more than 5 μg/g Cr. The gene discussed is FABP1; the disease is kidney disorder.